Loading...
Zevra Therapeutics, Inc.
ZVRA•NASDAQ
Healthcare
Biotechnology
$12.30
$0.74(6.40%)
Zevra Therapeutics, Inc. (ZVRA) Financial Performance & Statements
Review Zevra Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-14.02%
↓ 14.02%
Operating Income Growth
-75.40%
↓ 75.40%
Net Income Growth
-129.13%
↓ 129.13%
Operating Cash Flow Growth
-107.74%
↓ 107.74%
Operating Margin
-177.09%
↓ 177.09%
Gross Margin
78.84%
↑ 78.84%
Net Profit Margin
-226.64%
↓ 226.64%
ROE
-201.14%
↓ 201.14%
ROIC
-49.32%
↓ 49.32%
Zevra Therapeutics, Inc. (ZVRA) Financial Statements
Explore quarterly and annual reports for Zevra Therapeutics, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $12.04M | $3.69M | $4.45M | $3.42M |
| Cost of Revenue | $1.37M | $2.30M | $3.57M | $3.27M |
| Gross Profit | $10.68M | $1.39M | $876000.00 | $160000.00 |
| Gross Profit Ratio | $0.89 | $0.38 | $0.20 | $0.05 |
| R&D Expenses | $9.91M | $10.95M | $10.52M | $10.71M |
| SG&A Expenses | $16.13M | $16.21M | $12.60M | $9.93M |
| Operating Expenses | $26.09M | $28.70M | $24.67M | $20.65M |
| Total Costs & Expenses | $24.32M | $31.001M | $28.24M | $23.91M |
| Interest Income | -$73000.00 | $0.00 | $270000.00 | $929000.00 |
| Interest Expense | $2.19M | $1.26M | $2.11M | $735000.00 |
| Depreciation & Amortization | $1.65M | $1.62M | $1.56M | $1.56M |
| EBITDA | -$16.53M | -$29.30M | -$16.18M | -$14.39M |
| EBITDA Ratio | -$1.37 | -$7.93 | -$3.64 | -$4.20 |
| Operating Income | -$15.42M | -$27.31M | -$23.80M | -$20.49M |
| Operating Income Ratio | -$1.28 | -$7.39 | -$5.35 | -$5.98 |
| Other Income/Expenses (Net) | -$4.95M | -$5.92M | $3.94M | $3.79M |
| Income Before Tax | -$20.37M | -$33.23M | -$19.86M | -$16.69M |
| Income Before Tax Ratio | -$1.69 | -$8.99 | -$4.46 | -$4.87 |
| Income Tax Expense | $15.37M | $0.00 | $70000.00 | -$70000.00 |
| Net Income | -$35.74M | -$33.23M | -$19.93M | -$16.62M |
| Net Income Ratio | -$2.97 | -$8.99 | -$4.48 | -$4.85 |
| EPS | -$0.77 | -$0.69 | -$0.48 | -$0.40 |
| Diluted EPS | -$0.77 | -$0.69 | -$0.48 | -$0.40 |
| Weighted Avg Shares Outstanding | $53.67M | $47.81M | $41.90M | $41.78M |
| Weighted Avg Shares Outstanding (Diluted) | $53.67M | $47.81M | $41.90M | $41.78M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan